Journal DOI 10.68956/dyh5-kwte

Creative Commons source reading · Multiple sclerosis and neuroimmunology

The Role of B Cells and Antibodies in Multiple Sclerosis, Neuromyelitis Optica, and Related Disorders.

Silke Häusser-Kinzel; Martin S Weber

Originally published in Frontiers in immunology · 2019-02-08

From the article

Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.

Abstract

Our pathophysiological concept of the most common central nervous system demyelinating disease, multiple sclerosis, strikingly evolved by recent discoveries suggesting that B lymphocytes substantially contribute in its initiation and chronic propagation. In this regard, activated B cells are nowadays considered to act as important antigen-presenting cells for the activation of T cells and as essential source of pro-inflammatory cytokines. Hereby, they create a milieu in which other immune cells differentiate and join an orchestrated inflammatory infiltration of the CNS. Without a doubt, this scientific leap was critically pioneered by the empirical use of anti-CD20 antibodies in recent clinical MS trials, which revealed that the therapeutic removal of immature and mature B cells basically halted development of new inflammatory flares in otherwise relapsing MS patients. This stabilization occurred largely independent of any indirect effect on plasma cell-produced antibody levels.

Conclusion

Current research indicates that in MS, B cells contribute to the formation of relapses as well as to the progression of the disease independent of de novo CNS infiltration. In contrast, in NMO and anti-MOG antibody-associated demyelination, a peripherally generated CNS-targeting antibody response is suggested to be the main disease driver. Accordingly, these delineating disease entities may require MS-independent therapeutic strategies, a concept that is currently evolving.

Editorial reading guide

  • Which patient population and reference standard did the authors use?
  • Was the finding validated in a separate cohort, and how might patient selection affect it?